Nano-Enabled Therapeutics for Modulation of Immune Function
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 403
Special Issue Editors
Interests: nanomedicine; immunology; biocompatibility; toxicology; biochemistry; drug delivery
Special Issue Information
Dear Colleagues,
Nano-enabled therapeutics use nanoparticles to enhance the delivery and efficacy of therapeutic agents which, in turn, have the capability to modulate the immune system through enhancement or suppression. Nanoparticles are effective at targeting immune cells, such as dendritic cells, T cells, and macrophages, achieved through surface modifications that allow binding to specific receptors on immune cells, or by exploiting physicochemical properties allowing tissue penetration. Furthermore, nanoparticles have been utilized to deliver immunomodulatory agents, such as cytokines, to specific sites in the body. This has been achieved by encapsulating the agent within the nanoparticle or by conjugating the agent to the nanoparticle surface. These methods have been successful in modulating the immune response and have the potential to be used to treat a variety of immune-related diseases including cancer, autoimmune disorders, and infectious diseases. The potential for nano-enabled therapeutics to improve the delivery and efficacy of therapeutic agents while minimizing side effects is significant. It is likely that this research will lead to the development of new therapies for a wide range of immune-related diseases, and improve the overall treatment of these diseases.
This Special Issue seeks to highlight current progress in the development and implementation of nano-enabled therapeutics for modulation of immune function.
Dr. Christopher A.W. David
Dr. Marco Giardiello
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nano-enabled therapeutics
- nanomedicine
- nanoparticles
- biomaterials
- immunomodulation
- liposomes
- dendrimers
- polymers
- drug delivery systems
